| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0167-4781(98)00134-1 |
| P698 | PubMed publication ID | 9748560 |
| P2093 | author name string | K R Hande | |
| P2860 | cites work | Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma | Q28297805 |
| Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group | Q33488674 | ||
| Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. | Q34429779 | ||
| Chemotherapy of lung cancer | Q35234264 | ||
| Efficacy and safety of Stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma. The International SL-DOX Study Group | Q36138642 | ||
| Randomized comparison of etoposide pharmacokinetics after oral etoposide phosphate and oral etoposide | Q36421762 | ||
| Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer | Q36657495 | ||
| The biochemistry of P-glycoprotein-mediated multidrug resistance | Q38364215 | ||
| Etoposide (VP-16-213). Current status of an active anticancer drug | Q39492961 | ||
| The anthracycline antineoplastic drugs | Q40308244 | ||
| Secondary Leukemia Associated With a Conventional Dose of Etoposide: Review of Serial Germ Cell Tumor Protocols | Q40484262 | ||
| Topoisomerase inhibitors. A review of their therapeutic potential in cancer | Q40499871 | ||
| Potential role of oral anthracyclines in older patients with cancer | Q40679556 | ||
| Etoposide: current status and future perspectives in the management of malignant neoplasms | Q40694333 | ||
| Teniposide: overview of its therapeutic potential in adult cancers | Q40694338 | ||
| Epipodophyllotoxins in the treatment of childhood cancer | Q40694385 | ||
| Drugs ten years later: epirubicin. | Q40835543 | ||
| Detection and treatment of testicular cancer | Q40905676 | ||
| Acute leukemia in adults: recent developments in diagnosis and treatment. | Q41013256 | ||
| Antitopoisomerase drug action and resistance | Q41078123 | ||
| The importance of drug scheduling in cancer chemotherapy: etoposide as an example | Q41120799 | ||
| Cardiac toxicity 4 to 20 years after completing anthracycline therapy | Q41142694 | ||
| Conversion of the prodrug etoposide phosphate to etoposide in gastric juice and bile | Q41931919 | ||
| Comparison of idarubicin to daunomycin in a randomized multidrug treatment of childhood acute lymphoblastic leukemia at first bone marrow relapse: a report from the Children's Cancer Group | Q43580864 | ||
| Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study | Q44116567 | ||
| Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia | Q44461372 | ||
| Cyclophosphamide and fluorouracil combined with mitoxantrone versus doxorubicin for breast cancer: superiority of doxorubicin | Q48716555 | ||
| Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial. Medical Research Council Lung Cancer Working Party. | Q51014393 | ||
| Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. | Q53622998 | ||
| Epirubicin | Q59358984 | ||
| Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II | Q64390546 | ||
| Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response | Q67590955 | ||
| Increased teniposide clearance with concomitant anticonvulsant therapy | Q67733470 | ||
| Hodgkin's disease | Q67745351 | ||
| A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer | Q69355056 | ||
| Mitoxantrone: an overview of safety and toxicity | Q69900260 | ||
| Adriamycin-dependent release of iron from microsomal membranes | Q69938658 | ||
| Inhibition of the DNA catenation activity of type II topoisomerase by VP16-213 and VM26 | Q70221818 | ||
| Bioavailability of low-dose oral etoposide | Q70543559 | ||
| Anthracycline-induced cardiotoxicity | Q71112913 | ||
| Phase I evaluation of a water-soluble etoposide prodrug, etoposide phosphate, given as a 5-minute infusion on days 1, 3, and 5 in patients with solid tumors | Q72182761 | ||
| Bone marrow transplantation | Q72258978 | ||
| A phase I study of etoposide phosphate administered as a daily 30-minute infusion for 5 days | Q72281178 | ||
| Secondary acute myelogenous leukemia following safe exposure to etoposide | Q73437714 | ||
| Teniposide (VM-26) as a single drug treatment for patients with extensive small cell lung carcinoma: a Phase II study of the Southwest Oncology Group | Q73717512 | ||
| P433 | issue | 1-3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 173-184 | |
| P577 | publication date | 1998-10-01 | |
| P1433 | published in | Biochimica et Biophysica Acta | Q864239 |
| P1476 | title | Clinical applications of anticancer drugs targeted to topoisomerase II | |
| P478 | volume | 1400 |
| Q24627296 | (-)-Epigallocatechin gallate, a major constituent of green tea, poisons human type II topoisomerases |
| Q40938391 | A dual topoisomerase inhibitor, TAS-103, induces apoptosis in human cancer cells |
| Q28539430 | A high through-put screen for small molecules modulating MCM2 phosphorylation identifies Ryuvidine as an inducer of the DNA damage response |
| Q39079987 | A strand-passage conformation of DNA gyrase is required to allow the bacterial toxin, CcdB, to access its binding site |
| Q38359958 | A two-drug model for etoposide action against human topoisomerase IIalpha |
| Q91891315 | Activity of M3814, an Oral DNA-PK Inhibitor, In Combination with Topoisomerase II Inhibitors in Ovarian Cancer Models |
| Q44894718 | Activity of topoisomerase inhibitors daunorubicin, idarubicin, and aclarubicin in the Drosophila Somatic Mutation and Recombination Test |
| Q36136076 | Anti-proliferative effects of simocyclinone D8 (SD8), a novel catalytic inhibitor of topoisomerase II. |
| Q39811992 | Anticancer DNA intercalators cause p53-dependent mitochondrial DNA nucleoid re-modelling |
| Q38295973 | Base excision repair intermediates as topoisomerase II poisons |
| Q42370986 | Binding of two DNA molecules by type II topoisomerases for decatenation |
| Q36538243 | Cancer cell response to anthracyclines effects: mysteries of the hidden proteins associated with these drugs |
| Q33398170 | Catalytic inhibition of topoisomerase II by a novel rationally designed ATP-competitive purine analogue |
| Q36065491 | Clinical and In Vitro Studies on Impact of High-Dose Etoposide Pharmacokinetics Prior Allogeneic Hematopoietic Stem Cell Transplantation for Childhood Acute Lymphoblastic Leukemia on the Risk of Post-Transplant Leukemia Relapse |
| Q36394224 | Combination of Near Infrared Light-Activated Photodynamic Therapy Mediated by Indocyanine Green with Etoposide to Treat Non-Small-Cell Lung Cancer |
| Q35030777 | Contributions of the D-Ring to the activity of etoposide against human topoisomerase IIα: potential interactions with DNA in the ternary enzyme--drug--DNA complex. |
| Q42165294 | Correlation between chromosome damage and apoptosis induced by fludarabine and idarubicin in normal human lymphocytes |
| Q36719248 | Coupling between ATP binding and DNA cleavage by DNA topoisomerase II: A unifying kinetic and structural mechanism. |
| Q39737530 | Cribrostatin 6 induces death in cancer cells through a reactive oxygen species (ROS)-mediated mechanism |
| Q34688577 | Culprit and victim -- DNA topoisomerase II. |
| Q39886827 | DNA binding ellipticine analogues: synthesis, biological evaluation, and structure-activity relationships. |
| Q37412567 | DNA repair in Etoposide-induced DNA damage in lymphocytes of breast cancer patients and healthy women |
| Q58724813 | DNA topoisomerase 1 and 2A function as oncogenes in liver cancer and may be direct targets of nitidine chloride |
| Q36903197 | DNA topoisomerase II, genotoxicity, and cancer |
| Q24642324 | Dietary polyphenols as topoisomerase II poisons: B ring and C ring substituents determine the mechanism of enzyme-mediated DNA cleavage enhancement |
| Q43867902 | Differential antigenotoxic and cytoprotective effect of amifostine in idarubicin-treated mice |
| Q41672722 | Discovery of mono- and disubstituted 1H-pyrazolo[3,4]pyrimidines and 9H-purines as catalytic inhibitors of human DNA topoisomerase IIα. |
| Q44568992 | Doxorubicin and two of its analogues are preferential inducers of homologous recombination compared with mutational events in somatic cells of Drosophila melanogaster |
| Q30540353 | Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin |
| Q64076437 | Emerging small-molecule treatments for multiple sclerosis: focus on B cells |
| Q34895090 | Estrogen independent gene expression defines clinically relevant subgroups of estrogen receptor positive breast cancer |
| Q47193124 | Ethyl 3-oxo-2-(2,5-dioxopyrrolidin-3-yl)butanoate Derivatives: Anthelmintic and Cytotoxic Potentials, Antimicrobial, and Docking Studies |
| Q58693482 | Evaluation of intraductal delivery of poly(ethylene glycol)-doxorubicin conjugate nanocarriers for the treatment of ductal carcinoma in situ (DCIS)-like lesions in rats |
| Q39542339 | Formaldehyde activation of mitoxantrone yields CpG and CpA specific DNA adducts |
| Q44009060 | Formation and longevity of idarubicin-induced DNA topoisomerase II cleavable complexes in K562 human leukaemia cells. |
| Q34514751 | Gene expression levels of human shelterin complex and shelterin-associated factors regulated by the topoisomerase II inhibitors doxorubicin and etoposide in human cultured cells |
| Q40727880 | Genotoxicity of idarubicin and its modulation by vitamins C and E and amifostine |
| Q74038020 | Genotoxicity of several clinically used topoisomerase II inhibitors |
| Q38756222 | High-throughput assays for DNA gyrase and other topoisomerases |
| Q74311337 | Highly sensitive liquid chromatography-electrospray mass spectrometry (LC-MS) method for the determination of etoposide levels in human serum and plasma |
| Q38288542 | Human topoisomerase IIalpha possesses an intrinsic nucleic acid specificity for DNA ligation. Use of 5' covalently activated oligonucleotide substrates to study enzyme mechanism |
| Q59149996 | Imidazoles as potential anticancer agents |
| Q37184017 | Impact of the C-terminal domain of topoisomerase IIalpha on the DNA cleavage activity of the human enzyme |
| Q57214335 | In vitro and in vivo evaluation of etoposide - silk wafers for neuroblastoma treatment |
| Q74214743 | Induction of bulk and c-myc P2 promoter-specific DNA damage by an anti-topoisomerase II agent salvicine is an early event leading to apoptosis in HL-60 cells |
| Q24811057 | Induction of unique structural changes in guanine-rich DNA regions by the triazoloacridone C-1305, a topoisomerase II inhibitor with antitumor activities |
| Q33606082 | Influence of cell cycle and oncogene activity upon topoisomerase IIalpha expression and drug toxicity |
| Q45349901 | Inhibition of topoisomerase II α activity and induction of apoptosis in mammalian cells by semi-synthetic andrographolide analogues |
| Q34909651 | Interactions between the etoposide derivative F14512 and human type II topoisomerases: implications for the C4 spermine moiety in promoting enzyme-mediated DNA cleavage |
| Q29615223 | Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression |
| Q41693287 | Lysophosphatidic acid prevents apoptosis of Caco-2 colon cancer cells via activation of mitogen-activated protein kinase and phosphorylation of Bad. |
| Q37732974 | MYC in oncogenesis and as a target for cancer therapies |
| Q33647335 | Maurocalcine as a non toxic drug carrier overcomes doxorubicin resistance in the cancer cell line MDA-MB 231 |
| Q37334609 | Metnase mediates chromosome decatenation in acute leukemia cells |
| Q39668739 | Mixed pH-sensitive polymeric micelles for combination drug delivery |
| Q22254010 | Modulation of human DNA topoisomerase IIalpha function by interaction with 14-3-3epsilon |
| Q40218846 | Moxifloxacin enhances antiproliferative and apoptotic effects of etoposide but inhibits its proinflammatory effects in THP-1 and Jurkat cells |
| Q34459467 | NPRL-Z-1, as a new topoisomerase II poison, induces cell apoptosis and ROS generation in human renal carcinoma cells |
| Q39070001 | Natural compounds with P2X7 receptor-modulating properties |
| Q44179094 | Niacin deficiency increases spontaneous and etoposide-induced chromosomal instability in rat bone marrow cells in vivo |
| Q91604246 | Oncofetal HMGA2 attenuates genotoxic damage induced by topoisomerase II target compounds through the regulation of local DNA topology |
| Q37407949 | Overcoming target-mediated quinolone resistance in topoisomerase IV by introducing metal-ion-independent drug-enzyme interactions. |
| Q38962673 | Pharmacokinetics, antitumor and cardioprotective effects of liposome-encapsulated phenylaminoethyl selenide in human prostate cancer rodent models |
| Q37596167 | Phenanthriplatin Acts As a Covalent Poison of Topoisomerase II Cleavage Complexes |
| Q37658182 | Phytochemicals as Anticancer and Chemopreventive Topoisomerase II Poisons |
| Q44366709 | Profiling of differentially expressed apoptosis-related genes by cDNA arrays in human cord blood CD34+ cells treated with etoposide |
| Q31136132 | Purification of GidA protein, a novel topoisomerase II inhibitor produced by Streptomyces flavoviridis. |
| Q60710028 | Pyrrolo-quinoline derivatives as potential antineoplastic drugs |
| Q73236875 | Quinolones inhibit DNA religation mediated by Staphylococcus aureus topoisomerase IV. Changes in drug mechanism across evolutionary boundaries |
| Q24293748 | RECQL5 cooperates with Topoisomerase II alpha in DNA decatenation and cell cycle progression |
| Q35704726 | Rapid Identification of Chemoresistance Mechanisms Using Yeast DNA Mismatch Repair Mutants |
| Q64388057 | Salvicine, a novel DNA topoisomerase II inhibitor, exerting its effects by trapping enzyme-DNA cleavage complexes |
| Q33631024 | Sensitivity of human type II topoisomerases to DNA damage: stimulation of enzyme-mediated DNA cleavage by abasic, oxidized and alkylated lesions |
| Q44543805 | Site-specific DNA transesterification by vaccinia topoisomerase: effects of benzo[alpha]pyrene-dA, 8-oxoguanine, 8-oxoadenine and 2-aminopurine modifications |
| Q27649385 | Structural basis for gate-DNA recognition and bending by type IIA topoisomerases |
| Q37332317 | Substituents on etoposide that interact with human topoisomerase IIalpha in the binary enzyme-drug complex: contributions to etoposide binding and activity. |
| Q92958808 | Synthesis of novel, DNA binding heterocyclic dehydroabietylamine derivatives as potential antiproliferative and apoptosis-inducing agents |
| Q27687153 | Targeting mRNA for Alzheimer's and related dementias. |
| Q40537821 | Telomere length mediates the effects of telomerase on the cellular response to genotoxic stress |
| Q24300110 | The ATP-operated clamp of human DNA topoisomerase IIalpha: hyperstimulation of ATPase by "piggy-back" binding |
| Q40629555 | The combination of the antitumoural pyridyl cyanoguanidine CHS 828 and etoposide in vitro--from cytotoxic synergy to complete inhibition of apoptosis |
| Q40565443 | The cytoplasmic trafficking of DNA topoisomerase IIalpha correlates with etoposide resistance in human myeloma cells |
| Q34559593 | The geometry of DNA supercoils modulates the DNA cleavage activity of human topoisomerase I |
| Q36839637 | The geometry of DNA supercoils modulates topoisomerase-mediated DNA cleavage and enzyme response to anticancer drugs |
| Q36493495 | The role of chemotherapy in the treatment of malignant astrocytomas |
| Q37207935 | Topoisomerase I and IIalpha protein expression in primary colorectal cancer and recurrences following 5-fluorouracil-based adjuvant chemotherapy |
| Q33922870 | Topoisomerase II - drug interaction domains: identification of substituents on etoposide that interact with the enzyme. |
| Q33851826 | Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice |
| Q43589179 | Topoisomerase II from Chlorella virus PBCV-1 has an exceptionally high DNA cleavage activity |
| Q35770478 | Topoisomerase IIalpha in Wilms' tumour: gene alterations and immunoexpression. |
| Q35222177 | Yeast recombination pathways triggered by topoisomerase II-mediated DNA breaks |
Search more.